Kane Biotech Inc. KNBIF OTC

Kane Biotech Inc. (KNBIF) generated $-4.11M in operating cash flow for fiscal year 2024. After capital expenditures of $90.14K, free cash flow was $-4.2M.

Free cash flow margin was -201.9% of revenue. Cash conversion ratio was -0.67x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (43/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (100/100) — Cash conversion ratio was -0.67x suggests some earnings are non-cash items

Overall SharesGrow Score: 51/100 with 2/7 criteria passed.